Latest Candel Therapeutics News & Updates

See the latest news and media coverage for Candel. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Candel Therapeutics (Candel)

Clinical-stage biotech developing viral immunotherapy platforms for solid tumors

candeltx.com
Headquarters
Needham, United States
Founded year
1999
Company type
Public company
Number of employees
80–200
Industry
Pharmaceuticals

Last updated

Latest news about Candel Therapeutics (Candel)

In short: Candel Therapeutics advanced its oncology pipeline, highlighted by plans to submit a BLA for aglatimagene besadenovec in prostate cancer.

Company announcements

Candel

Candel Therapeutics reports extended clinical benefit in prostate cancer trial

Phase 3 trial of CAN-2409 shows 39% improvement in disease-free survival after prolonged follow-up, reinforcing potential to reduce tumor recurrence.

Unlock all announcements with a

Media coverage

The Globe and Mail

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene ...

Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing standard-of-care radiotherapy with curative intent...

Unlock all articles with a

Never miss news about Candel

Track Candel and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Candel competitors & trending companies

Browse news for competitors to Candel and other trending companies.